JPMorgan Chase & Co. Issues Positive Forecast for Cencora (NYSE:COR) Stock Price

Cencora (NYSE:COR) had its price objective lifted by equities researchers at JPMorgan Chase & Co. from $344.00 to $417.00 in a note issued to investors on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective suggests a potential upside of 14.10% from the company’s previous close.

COR has been the topic of several other research reports. Evercore ISI set a $400.00 price objective on shares of Cencora and gave the company an “outperform” rating in a report on Thursday. Morgan Stanley set a $330.00 price target on shares of Cencora and gave the company an “equal weight” rating in a research note on Wednesday, July 16th. Wall Street Zen raised shares of Cencora from a “hold” rating to a “buy” rating in a report on Saturday. Weiss Ratings reissued a “buy (b-)” rating on shares of Cencora in a report on Thursday, October 30th. Finally, Wells Fargo & Company upped their target price on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research report on Tuesday. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $371.09.

Cencora Stock Up 0.2%

NYSE:COR traded up $0.81 during midday trading on Tuesday, reaching $365.46. 126,395 shares of the stock traded hands, compared to its average volume of 1,535,519. The stock has a market capitalization of $70.85 billion, a PE ratio of 37.51, a price-to-earnings-growth ratio of 1.56 and a beta of 0.63. Cencora has a 12-month low of $223.92 and a 12-month high of $366.17. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90. The business has a 50-day moving average of $315.73 and a two-hundred day moving average of $300.12.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, beating the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. During the same quarter in the prior year, the business posted $3.34 EPS. The business’s revenue for the quarter was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, equities analysts forecast that Cencora will post 15.37 earnings per share for the current fiscal year.

Insider Activity

In other Cencora news, Chairman Steven H. Collis sold 31,350 shares of Cencora stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares in the company, valued at approximately $88,671,942.18. This trade represents a 9.30% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction dated Monday, October 20th. The shares were sold at an average price of $326.80, for a total value of $1,665,699.60. Following the completion of the transaction, the chief executive officer directly owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. This trade represents a 11.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 41,544 shares of company stock worth $12,230,941 over the last ninety days. 10.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Cencora

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Norges Bank purchased a new position in shares of Cencora during the 2nd quarter valued at approximately $695,215,000. Mizuho Markets Americas LLC grew its position in Cencora by 116.4% during the third quarter. Mizuho Markets Americas LLC now owns 212,800 shares of the company’s stock valued at $66,506,000 after buying an additional 1,511,906 shares during the period. Artisan Partners Limited Partnership acquired a new stake in Cencora during the second quarter valued at $411,888,000. Invesco Ltd. increased its holdings in Cencora by 42.1% in the first quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock valued at $1,281,429,000 after buying an additional 1,364,433 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Cencora by 5.3% in the second quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock worth $6,740,340,000 after acquiring an additional 1,125,661 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.